why choose us

First received: December 16, 2022

Clinical Trial: Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: Phase I Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab

Brief Summary: This phase I trial tests the safety and side effects of siltuximab in preventing CAR T cell therapy related cytokine release syndrome in patients with CD19 positive non-Hodgkin lymphoma.Several of the major complications of CD19 directed chimeric antigen receptor T-cell therapy (CD19.CAR-T) include cytokine release syndrome (CRS, a complication of a highly active immune system seen with some cancer treatments including CD19.CAR-T cell therapy) and immune effector cell therapy associated neurotoxicity (ICANS,…

Read more